The stock of Abivax ADR (ABVX) has seen a 0.68% increase in the past week, with a 0.78% gain in the past month, and a -6.15% decrease in the past quarter. The volatility ratio for the week is 3.48%, and the volatility levels for the past 30 days are at 4.74% for ABVX. The simple moving average for the past 20 days is 3.24% for ABVX’s stock, with a -19.09% simple moving average for the past 200 days.
Is It Worth Investing in Abivax ADR (NASDAQ: ABVX) Right Now?
ABVX has 36-month beta value of 0.55. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ABVX is 55.03M, and currently, short sellers hold a 0.41% ratio of that float. The average trading volume of ABVX on November 01, 2024 was 114.50K shares.
ABVX) stock’s latest price update
Abivax ADR (NASDAQ: ABVX) has seen a rise in its stock price by 0.48 in relation to its previous close of 10.32. However, the company has experienced a 0.68% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-07 that Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
Analysts’ Opinion of ABVX
Many brokerage firms have already submitted their reports for ABVX stocks, with Laidlaw repeating the rating for ABVX by listing it as a “Buy.” The predicted price for ABVX in the upcoming period, according to Laidlaw is $48 based on the research report published on July 29, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see ABVX reach a price target of $43. The rating they have provided for ABVX stocks is “Buy” according to the report published on May 20th, 2024.
Piper Sandler gave a rating of “Overweight” to ABVX, setting the target price at $42 in the report published on April 29th of the current year.
ABVX Trading at -5.52% from the 50-Day Moving Average
After a stumble in the market that brought ABVX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.07% of loss for the given period.
Volatility was left at 4.74%, however, over the last 30 days, the volatility rate increased by 3.48%, as shares surge +6.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.06% lower at present.
During the last 5 trading sessions, ABVX rose by +0.68%, which changed the moving average for the period of 200-days by -8.15% in comparison to the 20-day moving average, which settled at $10.05. In addition, Abivax ADR saw -3.08% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ABVX
The total capital return value is set at -0.51. Equity return is now at value -171.78, with -78.06 for asset returns.
Based on Abivax ADR (ABVX), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -1.81. The debt to equity ratio resting at 0.28. The interest coverage ratio of the stock is -6.47.
Currently, EBITDA for the company is -131.29 million with net debt to EBITDA at 1.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.04.
Conclusion
To put it simply, Abivax ADR (ABVX) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
